A new inhibitory checkpoint target hits the clinic
The hurly burly in Chicago between sessions
We have written about the positive and negative effects of various inhibitory checkpoints such as PD-L1, PD-L2, ICOS, and even B7-H3, but there are also other targets within the B7 family that might be worthwhile exploring in the clinic.
Beyond the hullabaloo surrounding the phase 3 anti-PD(L)1 data in 1L NSCLC, there were actually a lot of interesting new and emerging molecules that caught our attention from small biotechs that we plan to highlight throughout the rest of this week. They all have different targets, approaches and rationales, but offer a window into the world of oncology R&D and where things might be headed in the next couple of years.
Today we take a look at one of the long forgotten checkpoint targets and explore a number of aspects that can be considered, given that several companies have preclinical or clinical molecules in early development.
Is this an IO target to watch out for – or not? What are the challenges and opportunities to consider?
It turns out that there could be more than one way to unleash T cells on cancer… as this interview with a company scientist and researcher demonstrates.
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
